Abstract
Get full access to this article
View all access options for this article.
References
1.
Kebebew
E
,
Greenspan
FS
,
Clark
OH
,
Woeber
KA
,
McMillan
A
. 2005 . Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors . Cancer , 103 :1330 –1335 .
2.
Tsongalis
GJ
,
Peterson
JD
,
de Abreu
FB
,
Tunkey
CD
,
Gallagher
TL
,
Strausbaugh
LD
,
Wells
WA
,
Amos
CI
. 2014 . Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations . Clin Chem Lab Med , 52 :707 –714 .
3.
Hyman
DM
,
Puzanov
I
,
Subbiah
V
,
Faris
JE
,
Chau
I
,
Blay
JY
,
Wolf
J
,
Raje
NS
,
Diamond
EL
,
Hollebecque
A
,
Gervais
R
,
Elez-Fernandez
ME
,
Italiano
A
,
Hofheinz
RD
,
Hidalgo
M
,
Chan
E
,
Schuler
M
,
Lasserre
SF
,
Makrutzki
M
,
Sirzen
F
,
Veronese
ML
,
Tabernero
J
,
Baselga
J
. 2015 . Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations . N Engl J Med , 373 :726 –736 .
4.
Rosove
MH
,
Peddi
PF
,
Glaspy
JA
. 2013 .
BRAF V600E inhibition in anaplastic thyroid cancer . N Engl J Med , 368 :684 –685 .